GnRH-a-1M
PreclinicalSmall molecule
GnRH-a-1M is one of 22 small molecule programs targeting Adenomyosis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Adenomyosis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Femara
NovartisApproved
Zoladex
TTerSera Therapeutics LLC
Approved
Prometrium
FerringPhase 3
Ofev
Boehringer IngelheimPhase 3
Gnrh Agonist
Johnson & JohnsonPhase 3
Enantone
TakedaApproved
Mifeprex
DDanco
Phase 2
Gnrh Analog
MMemorial Sloan Kettering Cancer Center
Approved
Ulipristal Acetate
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GnRH-a-1M. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details